Imran Alibhai

Company: Tvardi Therapeutics

Job title: Chief Executive Officer

Seminars:

Panel Discussion: Unravelling the Rationale Behind Combination Therapy & Critical Design & Development Considerations for Emerging Therapeutic Candidates 3:15 pm

• Exploring the current limitations of single agent therapeutics and the scientific rationale behind targeting multiple pathways and processes for enhanced efficacy in halting fibrosis • Critical considerations into clinical trial design in combination therapy including patient population selection based on specific signatures predicting a better response to combination • Defining appropriate endpoints for combination…Read more

day: Day Two

Unveiling TTI-101 as a Novel Approach in Pulmonary Fibrosis & Interstitial Lung Disease Treatment 4:15 pm

• Exploring TTI-101, an orally bioavailable, small-molecule inhibitor of signal transducer and activator of transcription 3 (STAT3) and its implications in IPF and ILD • Examining the comprehensive Phase 2 multicenter study of TTI-101, explore the study’s scope, objectives, patient selection criteria, endpoint selection, and the study methodologyRead more

day: Day Two